Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice

Wencheng Liu, Lingzhi Zhao, Brittany Blackman, Mayur Parmar, Man Ying Wong, Thomas Woo, Fangmin Yu, Dolan Sondhi, Stephen M. Kaminsky, Ronald Crystal, Steven M. Paul

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ~40–50% in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons. Hippocampal antibody levels achieved after AAV delivery were ~50-fold more than those reported following repeated systemic administration. In contrast to systemic passive immunization, we observed markedly reduced (≥80–90%) hippocampal insoluble pathological tau species and neurofibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV-IgG control vector. Moreover, the hippocampal atrophy observed in untreated P301S mice was fully rescued by treatment with the AAV-vectored PHF1 antibody. Vectored passive immunotherapy with an anti-tau monoclonal antibody may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy, or Alzheimer’s disease.

Original languageEnglish
Pages (from-to)12425-12435
Number of pages11
JournalJournal of Neuroscience
Volume36
Issue number49
DOIs
Publication statusPublished - 7 Dec 2016
Externally publishedYes

Fingerprint

Dependovirus
Transgenic Mice
Immunization
Monoclonal Antibodies
Passive Immunization
Pathology
Antibodies
Tauopathies
Progressive Supranuclear Palsy
Frontotemporal Dementia
Neurofibrillary Tangles
Atrophy
Alzheimer Disease
Immunoglobulin G
Neurons
Brain
Therapeutics

Keywords

  • AAV vector
  • Alzheimer’s disease
  • Anti-tau antibody
  • Passive immunization
  • PHF-tau
  • Tauopathy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. / Liu, Wencheng; Zhao, Lingzhi; Blackman, Brittany; Parmar, Mayur; Wong, Man Ying; Woo, Thomas; Yu, Fangmin; Sondhi, Dolan; Kaminsky, Stephen M.; Crystal, Ronald; Paul, Steven M.

In: Journal of Neuroscience, Vol. 36, No. 49, 07.12.2016, p. 12425-12435.

Research output: Contribution to journalArticle

Liu, W, Zhao, L, Blackman, B, Parmar, M, Wong, MY, Woo, T, Yu, F, Sondhi, D, Kaminsky, SM, Crystal, R & Paul, SM 2016, 'Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice', Journal of Neuroscience, vol. 36, no. 49, pp. 12425-12435. https://doi.org/10.1523/JNEUROSCI.2016-16.2016
Liu, Wencheng ; Zhao, Lingzhi ; Blackman, Brittany ; Parmar, Mayur ; Wong, Man Ying ; Woo, Thomas ; Yu, Fangmin ; Sondhi, Dolan ; Kaminsky, Stephen M. ; Crystal, Ronald ; Paul, Steven M. / Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. In: Journal of Neuroscience. 2016 ; Vol. 36, No. 49. pp. 12425-12435.
@article{13e7325eac964281a5a7fe7e2a52d4e0,
title = "Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice",
abstract = "Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ~40–50{\%} in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons. Hippocampal antibody levels achieved after AAV delivery were ~50-fold more than those reported following repeated systemic administration. In contrast to systemic passive immunization, we observed markedly reduced (≥80–90{\%}) hippocampal insoluble pathological tau species and neurofibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV-IgG control vector. Moreover, the hippocampal atrophy observed in untreated P301S mice was fully rescued by treatment with the AAV-vectored PHF1 antibody. Vectored passive immunotherapy with an anti-tau monoclonal antibody may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy, or Alzheimer’s disease.",
keywords = "AAV vector, Alzheimer’s disease, Anti-tau antibody, Passive immunization, PHF-tau, Tauopathy",
author = "Wencheng Liu and Lingzhi Zhao and Brittany Blackman and Mayur Parmar and Wong, {Man Ying} and Thomas Woo and Fangmin Yu and Dolan Sondhi and Kaminsky, {Stephen M.} and Ronald Crystal and Paul, {Steven M.}",
year = "2016",
month = "12",
day = "7",
doi = "10.1523/JNEUROSCI.2016-16.2016",
language = "English",
volume = "36",
pages = "12425--12435",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "49",

}

TY - JOUR

T1 - Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice

AU - Liu, Wencheng

AU - Zhao, Lingzhi

AU - Blackman, Brittany

AU - Parmar, Mayur

AU - Wong, Man Ying

AU - Woo, Thomas

AU - Yu, Fangmin

AU - Sondhi, Dolan

AU - Kaminsky, Stephen M.

AU - Crystal, Ronald

AU - Paul, Steven M.

PY - 2016/12/7

Y1 - 2016/12/7

N2 - Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ~40–50% in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons. Hippocampal antibody levels achieved after AAV delivery were ~50-fold more than those reported following repeated systemic administration. In contrast to systemic passive immunization, we observed markedly reduced (≥80–90%) hippocampal insoluble pathological tau species and neurofibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV-IgG control vector. Moreover, the hippocampal atrophy observed in untreated P301S mice was fully rescued by treatment with the AAV-vectored PHF1 antibody. Vectored passive immunotherapy with an anti-tau monoclonal antibody may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy, or Alzheimer’s disease.

AB - Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ~40–50% in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons. Hippocampal antibody levels achieved after AAV delivery were ~50-fold more than those reported following repeated systemic administration. In contrast to systemic passive immunization, we observed markedly reduced (≥80–90%) hippocampal insoluble pathological tau species and neurofibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV-IgG control vector. Moreover, the hippocampal atrophy observed in untreated P301S mice was fully rescued by treatment with the AAV-vectored PHF1 antibody. Vectored passive immunotherapy with an anti-tau monoclonal antibody may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy, or Alzheimer’s disease.

KW - AAV vector

KW - Alzheimer’s disease

KW - Anti-tau antibody

KW - Passive immunization

KW - PHF-tau

KW - Tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85006022210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006022210&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.2016-16.2016

DO - 10.1523/JNEUROSCI.2016-16.2016

M3 - Article

C2 - 27927959

AN - SCOPUS:85006022210

VL - 36

SP - 12425

EP - 12435

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 49

ER -